Sherlock Biosciences: Bryan Dechairo
Sherlock Biosciences has appointed Bryan Dechairo as president and CEO. He will also join Sherlock’s board of directors. Dechairo succeeds cofounder Rahul Dhanda, who will continue to serve as a board member until the end of 2021, and then as a strategic adviser in 2022.
Dechairo joins Sherlock from Myriad Genetics, where he served as executive VP of clinical development and oversaw the company's development portfolio. Before joining Myriad, he served as chief medical officer, CSO, and senior VP of research and development at Assurex Health, which was acquired by Myriad in 2016. Prior to Assurex Health, Dechairo held roles of increasing responsibility at Medco Health Solutions, Pfizer, and other diagnostic and therapeutics companies. He also served on the board of directors for the National Alliance on Mental Illness.